RCS - Ondine Biomedical - Ondine Presented Steriwave Data at IPC 2026

Ondine BiomedicalAnnouncement

30/04/2026 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260430:nRSd5825Ca&default-theme=true

RNS Number : 5825C  Ondine Biomedical Inc.  30 April 2026

30 April 2026

ONDINE BIOMEDICAL INC.

("Ondine" or the "Company")

Ondine Biomedical Presented Steriwave Data at Recent Infection Prevention and
Control Conference (IPC 2026)

Ondine Biomedical Inc. (LON: OBI), a leader in light-activated antimicrobial
therapies, announces that its President and Chief Technology Officer, Dr.
Nicolas Loebel, was a featured speaker at the Infection Prevention and Control
("IPC") Conference. The event took place 28-29 April at The National
Conference Centre in Birmingham and brought together leading clinicians,
infection prevention specialists, and NHS decision-makers from across the UK.

The IPC Conference 2026 featured sessions addressing strategies to reduce
healthcare-associated infections ("HAIs"), improve antimicrobial stewardship,
and address operational pressures within the NHS. The program included
expert-led sessions on surveillance and early identification of infection
risks, practical containment strategies, and scalable interventions to improve
patient safety while reducing costs. The conference also highlighted the
urgent need for innovation-driven solutions to address increasing surgical
backlogs, workforce constraints, and the growing burden of antimicrobial
resistance ("AMR").

In alignment with the conference's focus on evidence-based best practices and
innovation adoption, Ondine Biomedical presented clinical outcomes associated
with its Steriwave(®) nasal photodisinfection, which NHS Supply Chain
recently classified as an Innovation Product. This classification reflects
Steriwave's alignment with long-term NHS priorities, including reducing AMR,
supporting infection prevention, and improving the efficiency and
sustainability of healthcare delivery.

Dr. Loebel's presentation, titled "Nasal Photodisinfection: Addressing the
Hidden Costs of HAIs", focused on the clinical and economic burden of
healthcare-associated infections and the role of nasal decolonisation in
reducing infection risk. The presentation highlighted limitations of
traditional approaches and outlined how Steriwave nasal photodisinfection
offers a compelling non-antibiotic alternative aligned with evolving
antimicrobial stewardship priorities.

Key highlights from the presentation included:

·     Burden of HAIs: Healthcare-associated infections drive significant
clinical and economic impact, including increased length of stay, higher
treatment costs, and reduced surgical capacity. With an average of 9.7
additional hospital days per major SSI, each infection can displace two to
three subsequent surgical procedures.

·     Limitations of antibiotic decolonisation: The presentation
outlined challenges associated with antibiotic-based nasal decolonisation,
including resistance development, multi-day treatment protocols, and
disruption of the nasal microbiome.

·     Photodisinfection mechanism and profile: Steriwave nasal
photodisinfection was presented as a rapid, single-dose, broad-spectrum
antimicrobial approach designed to eliminate nasal pathogens without
contributing to antimicrobial resistance. The nurse-led application supports
consistent, high compliance.

·    Clinical and real-world data: Data from Steriwave use across
multiple clinical and real-world settings in Canada and the UK were presented,
including reductions in surgical site infections and ICU-acquired pneumonia.
These findings were associated with shorter lengths of stay, faster recovery,
and improved patient flow, supporting hospitals in reclaiming bed capacity and
increasing procedural throughput.

·  Health economic impact: Health economic analysis of Steriwave was
highlighted, demonstrating substantial reductions in infection-related costs
and improved hospital efficiency, supporting more sustainable NHS operations.

Dr. Nicolas Loebel remarked:

"Hospital-acquired infections are not only a clinical challenge but also place
a significant logistical and financial burden on healthcare systems. Our nasal
photodisinfection helps clinicians to proactively protect patients while
improving efficiency and capacity within their facilities in an era of rising
antimicrobial resistance."

Carolyn Cross, Ondine's CEO added:

"Ondine's participation in IPC 2026 reflects the growing interest we are
seeing in the UK market and engagement with NHS institutions around
non-antibiotic approaches to infection prevention. Steriwave's recent
classification as an Innovation Product by NHS Supply Chain further reinforces
this momentum and its alignment with NHS priorities, including improving
patient outcomes while managing costs."

 

Enquiries:

 Ondine Biomedical Inc.                            www.ondinebio.com (http://www.ondinebio.com)
 Carolyn Cross, CEO                                +1 604 669 0555

or via 5654 & Company

 Strand Hanson Limited (Nominated Adviser & Joint Financial Adviser)
 James Harris, Richard Johnson                     +44 (0)20 7409 3494

 Peel Hunt LLP (Joint Bookrunner and Broker, Joint Financial Adviser)
 James Steel, Sohail Akbar                         +44 (0)20 7418 8900

 5654 & Company (Financial PR and IR Adviser)      ondinebiomedical@5654.co.uk (mailto:ondinebiomedical@5654.co.uk)
 Matthew Neal, Chris Gardner, Melissa Gardiner     +44 0791 7800 011

+44 0775 7697 357

 

 

About Steriwave(®) and its Mode of Action

Steriwave nasal photodisinfection is a non-invasive and painless treatment
that uses a proprietary light-activated photosensitive agent to destroy
harmful bacteria, viruses, and fungi, including antibiotic-resistant strains,
in the nasal passages. The procedure takes five minutes and, unlike
antibiotics, is effective immediately and allows the normal nasal microbiome
to recover quickly, without fostering antimicrobial resistance.

The two-step process involves applying the Steriwave formulation in the
nostrils where it electrostatically binds to microbes rather than human cells.
The area is then illuminated with safe red light to activate the formulation,
triggering an oxidative burst that physically destroys all manner of pathogens
within minutes. This rapid and overwhelming oxidative stress makes it
extremely difficult for pathogens to develop resistance, and the process stops
immediately once the light is turned off. Steriwave has been used in a growing
number of hospitals since 2011.

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved
for nasal decolonisation in Canada, Australia, Mexico and several other
countries under the name Steriwave(®). In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track status by the
FDA and is currently undergoing clinical trials for regulatory approval.
Products beyond nasal photodisinfection include therapies for a variety of
medical indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAIMMRTMTAJMPF



            Copyright 2019 Regulatory News Service, all rights reserved